Despite the availability of preventative vaccines, 2 billion people worldwide have been infected with hepatitis B virus (HBV). Over 250 million of those infected progress to chronic HBV infection and become susceptible to life threatening liver disease. Avalia’s therapy aims to provide a necessary cure for these individuals.